| Name | Tipranavir |
| Description | Tipranavir is a protease inhibitor that inhibits HIV-1 resistant to more than 1 protease inhibitor .Tipranavir effectively inhibits HIV-1 protease enzyme activity and dimerisation and has potent activity against multiple protease inhibitor (PI) HIV-1 isolates (IC50 of 66-410 nM). Tipranavir inhibits SARS-CoV-2 3CLpro activity. |
| In vitro | Tipranavir (PNU-140690) inhibits HIV-1 protease activity, blocks protease subunit dimerization, and exhibits potent efficacy against a broad range of wild-type and multi-PI-resistant HIV-1 variants.[1] |
| In vivo | Tipranavir (5 mg/kg ; mouse model): CLtot was 0.17 ± 0.10 L/h/kg, Vss was 0.51 ± 0.14 L/kg, and t1/2 was 5.4 ±0. 3h.[4]
Tipranavir (10 mg/kg ; oral ; rats): got the result of F was 30% compared to 5 mg/kg tipranavir dosing.[4] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 45 mg/mL (74.67 mM), Sonication is recommended.
DMSO : 260 mg/mL (431.42 mM), Sonication is recommended.
|
| Keywords | Tipranavir | SARSCoV | SARS CoV-1 3CLpro | PNU140690 | PNU 140690 | HIVProtease | HIV-1 protease | HIV Protease |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Emtricitabine | Dolutegravir intermediate-1 | Dimethyl fumarate | Hydroxychloroquine | Lamivudine | Valproic Acid | α-Cyclodextrin | (-)-Epigallocatechin Gallate | Decanedioic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Bioactive Compound Library | Drug-induced Liver Injury (DILI) Compound Library | EMA Approved Drug Library | Protease Inhibitor Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Infection Compound Library | Human Metabolite Library |
United States
